TAAR1 agonists, including the Phase 3 clinical development candidate ulotaront, have recently emerged as a potential new treatment approach in schizophrenia and other psychiatric disorders including depression, anxiety and substance abuse [1,59,60]. This evidence concerns the gene TAAR1 and schizophrenia.